N
Nobuyuki Okamura
Researcher at Tohoku Pharmaceutical University
Publications - 264
Citations - 9470
Nobuyuki Okamura is an academic researcher from Tohoku Pharmaceutical University. The author has contributed to research in topics: Alzheimer's disease & Dementia. The author has an hindex of 47, co-authored 247 publications receiving 8137 citations. Previous affiliations of Nobuyuki Okamura include Tohoku University & German Center for Neurodegenerative Diseases.
Papers
More filters
Journal ArticleDOI
Imaging of Tau Pathology in a Tauopathy Mouse Model and in Alzheimer Patients Compared to Normal Controls
Masahiro Maruyama,Hitoshi Shimada,Tetsuya Suhara,Hitoshi Shinotoh,Bin Ji,Jun Maeda,Ming-Rong Zhang,John Q. Trojanowski,Virginia M.-Y. Lee,Maiko Ono,Kazuto Masamoto,Harumasa Takano,Naruhiko Sahara,Naruhiko Sahara,Nobuhisa Iwata,Nobuyuki Okamura,Shozo Furumoto,Yukitsuka Kudo,Qing Chang,Takaomi C. Saido,Akihiko Takashima,Jada Lewis,Ming Kuei Jang,Ichio Aoki,Hiroshi Ito,Makoto Higuchi +25 more
TL;DR: A class of tau ligands, phenyl/pyridinyl-butadienyl-benzothiazoles/benZothiazoliums (PBBs), for visualizing diverse tau inclusions in brains of living patients with AD or non-AD tauopathies and animal models of these disorders are developed.
Journal ArticleDOI
18F-THK523: a novel in vivo tau imaging ligand for Alzheimer’s disease
Michelle T. Fodero-Tavoletti,Nobuyuki Okamura,Shozo Furumoto,Rachel S. Mulligan,Andrea R Connor,Catriona McLean,Diana Cao,Angela Rigopoulos,Glenn A Cartwright,Graeme O'Keefe,Sylvia J. Gong,Paul A. Adlard,Paul A. Adlard,Kevin J. Barnham,Kevin J. Barnham,Christopher C. Rowe,Colin L. Masters,Yukitsuka Kudo,Roberto Cappai,Kazuhiko Yanai,Victor L. Villemagne,Victor L. Villemagne +21 more
TL;DR: The preclinical examination of THK523 has demonstrated its high affinity and selectivity for tau pathology both in vitro and in vivo, indicating that (18)F-THK523 fulfils ligand criteria for human imaging trials.
Journal ArticleDOI
18F-THK5351: A Novel PET Radiotracer for Imaging Neurofibrillary Pathology in Alzheimer Disease.
Ryuichi Harada,Nobuyuki Okamura,Shozo Furumoto,Katsutoshi Furukawa,Aiko Ishiki,Naoki Tomita,Tetsuro Tago,Kotaro Hiraoka,Shoichi Watanuki,Miho Shidahara,Masayasu Miyake,Yoichi Ishikawa,Rin Matsuda,Akie Inami,Takeo Yoshikawa,Yoshihito Funaki,Ren Iwata,Manabu Tashiro,Kazuhiko Yanai,Hiroyuki Arai,Yukitsuka Kudo +20 more
TL;DR: A novel tau PET tracer is developed through compound optimization of arylquinoline derivatives that bound to neurofibrillary tangles selectively and with a higher signal-to-background ratio than did THK5117 in Alzheimer disease patients.
Journal ArticleDOI
Novel 18F-labeled arylquinoline derivatives for noninvasive imaging of tau pathology in Alzheimer disease.
Nobuyuki Okamura,Shozo Furumoto,Ryuichi Harada,Tetsuro Tago,Takeo Yoshikawa,Michelle T. Fodero-Tavoletti,Rachel S. Mulligan,Victor L. Villemagne,Hiroyasu Akatsu,Takayuki Yamamoto,Hiroyuki Arai,Ren Iwata,Kazuhiko Yanai,Yukitsuka Kudo +13 more
TL;DR: Novel 18F-labeled arylquinoline derivatives are developed, which showed that these radiotracers preferentially bound to neurofibrillary tangles and neuropil threads, which colocalized with Gallyas-positive and immunoreactive tau protein deposits in AD brain sections.
Journal ArticleDOI
Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain
Kok Pin Ng,Tharick A. Pascoal,Sulantha Mathotaarachchi,Joseph Therriault,Min Su Kang,Monica Shin,Marie-Christine Guiot,Qi Guo,Ryuichi Harada,Robert A. Comley,Gassan Massarweh,Jean-Paul Soucy,Nobuyuki Okamura,Serge Gauthier,Pedro Rosa-Neto +14 more
TL;DR: The results indicate that the interpretation of 18F-THK5351 PET images, with respect to tau, is confounded by the high MAO-B availability across the entire brain.